Goldenseal for Health & Longevity - Quick Reference Sheet

Goldenseal for Health & Longevity

Created on 07/26/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

Goldenseal is a traditional root, but its active plant compound is barely absorbed when swallowed, so whole-body "natural antibiotic" effects are unlikely. The most plausible benefits are local — gut, mouth, and skin — on weak evidence. Its clearest effect is slowing how the body clears many medications, and product contamination is common. (Full Review)

Protocol

Dose
0.5–1 g root
Dried root, or 0.3–1 mL of a 1:5 tincture
Frequency
2–3× daily
Split dosing, in short courses
Timing
With meals
Maximizes gut contact, reduces stomach upset
Time to effect
Local Relief
Within days
Gut and mucous-membrane use during an acute course
Loading Period
None
No meaningful loading phase
Systemic Benefit
Not expected
No long-term whole-body effect

Benefits

Contraindications
  • Pregnancy
  • Nursing mothers, neonates, and infants
  • Significant liver disease
  • Transplant recipients or others on narrow-margin medications
Key Interactions
  • CYP3A4 drugs (statins, cyclosporine, tacrolimus, felodipine, midazolam)
  • CYP2D6 drugs (metoprolol, antidepressants, tamoxifen)
  • Metformin
  • OTC dextromethorphan, antihistamines, pain relievers
  • Additive glucose- or blood-pressure-lowering supplements (berberine, cinnamon, alpha-lipoic acid)
  • Enzyme-modifying botanicals (St. John's wort)

Risk & Side Effects

  • High: Herb–drug interactions
  • Medium: Product contamination and adulteration; pregnancy, nursing, and neonatal harm
  • Low: Gastrointestinal and mucous-membrane irritation; additive blood-sugar and blood-pressure lowering
  • Speculative: Phototoxicity; hepatotoxicity at high exposure; neurotoxicity at high exposure

Monitoring

Marker Target Why
ALT / AST ALT ~10–26 U/L; AST ~10–26 U/L Screen for the possible liver toxicity signal
Total & direct bilirubin Total ~0.3–1.0 mg/dL Berberine can displace bilirubin
Fasting blood glucose 75–90 mg/dL Detects additive blood-sugar lowering when stacked
Fasting lipid panel LDL <100; triglycerides <100; HDL >50 mg/dL Context for any cholesterol effect
Interacting-drug levels Within each drug's therapeutic window Catches enzyme-inhibition interactions before toxicity

Cadence: No routine repeat labs for a short 1–3 week course; for repeated or prolonged use, recheck liver enzymes and bilirubin at 4–8 weeks, then every 6–12 months, and monitor glucose more frequently when combined with glucose-lowering agents.

Qualitative Assessment

  • Digestive comfort and stool pattern
  • Energy and general well-being
  • Yellowing of skin or eyes, dark urine, or unusual fatigue
  • Signs of low blood sugar or low blood pressure when stacked with other agents